Eledon Pharmaceuticals, Inc. (ELDN)
Automate Your Wheel Strategy on ELDN
With Tiblio's Option Bot, you can configure your own wheel strategy including ELDN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ELDN
- Rev/Share 0.005
- Book/Share 1.1801
- PB 3.3385
- Debt/Equity 0.0204
- CurrentRatio 6.7362
- ROIC -0.75
- MktCap 91722418.0
- FreeCF/Share -0.8714
- PFCF -1.3642
- PE -1.4795
- Debt/Assets 0.0056
- DivYield 0
- ROE -0.8531
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 2
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | ELDN | H.C. Wainwright | -- | Buy | -- | $9 | June 18, 2025 |
| Initiation | ELDN | Guggenheim | -- | Buy | -- | $9 | Jan. 28, 2025 |
News
Eledon Pharmaceuticals, Inc. (ELDN) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript
Published: November 17, 2025 by: Seeking Alpha
Sentiment: Neutral
Eledon Pharmaceuticals, Inc. ( ELDN ) Guggenheim Securities 2nd Annual Healthcare Innovation Conference November 12, 2025 10:30 AM EST Company Participants Steven Perrin - President, Chief Scientific Officer & Non Independent Director Conference Call Participants Vamil Divan - Guggenheim Securities, LLC, Research Division Presentation Vamil Divan Guggenheim Securities, LLC, Research Division All right. Thanks, everyone, for joining us here on the Second Annual Guggenheim Healthcare Innovation Conference.
Read More
Eledon Pharmaceuticals, Inc. (ELDN) Discusses Phase II BESTOW Trial Results and Advances in Transplantation Immunosuppression Transcript
Published: November 07, 2025 by: Seeking Alpha
Sentiment: Neutral
Eledon Pharmaceuticals, Inc. ( ELDN ) Discusses Phase II BESTOW Trial Results and Advances in Transplantation Immunosuppression November 7, 2025 8:00 AM EST Company Participants David-Alexandre Gros - CEO & Non Independent Director Eliezer Katz - Chief Medical Officer Steven Perrin - President, Chief Scientific Officer & Non Independent Director Paul Little - Chief Financial Officer Conference Call Participants Thomas Smith - Leerink Partners LLC, Research Division Pete Stavropoulos - Cantor Fitzgerald & Co., Research Division Rami Katkhuda - LifeSci Capital, LLC, Research Division Vamil Divan - Guggenheim Securities, LLC, Research Division Robert LeBoyer - NOBLE Capital Markets, Inc., Research …
Read More
Eledon Pharmaceuticals' Lead Asset Fails In Mid-Stage Study, But Pushes Forward With Pivotal Study
Published: November 07, 2025 by: Benzinga
Sentiment: Negative
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) stock is trading lower on Friday, with a session volume of 15.72 million, compared to its average volume of 1.24 million, according to Benzinga Pro. The company announced results from its Phase 2 BESTOW trial of tegoprubart for the prevention of organ rejection in patients receiving a de novo kidney transplant.
Read More
Best Momentum Stocks to Buy for July 14th
Published: July 14, 2025 by: Zacks Investment Research
Sentiment: Positive
ELDN, KDDIY and PENG made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 14, 2025.
Read More
New Strong Buy Stocks for July 14th
Published: July 14, 2025 by: Zacks Investment Research
Sentiment: Positive
WIT, KNOP, PENG, ELDN and KDDIY have been added to the Zacks Rank #1 (Strong Buy) List on July 14, 2025.
Read More
What Makes Eledon Pharmaceuticals (ELDN) a New Buy Stock
Published: May 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Eledon Pharmaceuticals (ELDN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
About Eledon Pharmaceuticals, Inc. (ELDN)
- IPO Date 2014-09-17
- Website https://eledon.com
- Industry Biotechnology
- CEO David-Alexandre C. Gros
- Employees 31